INTERVIEW: Scottish Medicines Consortium – future-proofing for personalized medicines
This article was originally published in Scrip
News that Scotland is to develop its own value-based assessments for drugs, rather than wait for England to finally come through with its own value-based pricing system, came as something as a relief for Angela Timoney, chair of Scotland's influential health technology appraisal institute, the Scottish Medicines Consortium. The decision means that SMC can finally move forward with changing the way it assesses and-of-life and ultra-orphan drugs, which in turn will help prepare for a future that will inevitably mean dealing with more personalized medicines, she told Scrip.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.